MRUS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Merus BV

NASDAQ | MRUS

68.17

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 17, 2025)

$5.06B

Market Cap

-

P/E Ratio

-5.58

EPS

$70.65

52 Week High

$33.19

52 Week Low

HEALTHCARE

Sector

MRUS Chart

Recent Chart
Price Action

MRUS Technicals

Tags:

MRUS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $36M
Total Revenue $36M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$272M
Selling General And Administrative $83M
Research And Development $225M
Operating Expenses $308M
Investment Income Net -
Net Interest Income $31M
Interest Income -
Interest Expense $31M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.5M
Income Before Tax -$207M
Income Tax Expense $8.2M
Interest And Debt Expense -
Net Income From Continuing Operations -$215M
Comprehensive Income Net Of Tax -
Ebit -$272M
Ebitda -$270M
Net Income -$215M

Revenue & Profitability

Earnings Performance

MRUS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $785M
Total Current Assets $569M
Cash And Cash Equivalents At Carrying Value $293M
Cash And Short Term Investments $293M
Inventory -
Current Net Receivables $4.7M
Total Non Current Assets $214M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $1.7M
Intangible Assets Excluding Goodwill $1.7M
Goodwill -
Investments -
Long Term Investments $187M
Short Term Investments $244M
Other Current Assets $27M
Other Non Current Assets -
Total Liabilities $135M
Total Current Liabilities $87M
Current Accounts Payable $4.2M
Deferred Revenue -
Current Debt -
Short Term Debt $1.7M
Total Non Current Liabilities $50M
Capital Lease Obligations $9.9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $9.9M
Other Current Liabilities $44M
Other Non Current Liabilities -
Total Shareholder Equity $648M
Treasury Stock -
Retained Earnings -$968M
Common Stock $7M
Common Stock Shares Outstanding $64M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$186M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.5M
Capital Expenditures $1.7M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$220M
Cashflow From Financing $494M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$215M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $36M
Total Revenue $36M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$272M
Selling General And Administrative $83M
Research And Development $225M
Operating Expenses $308M
Investment Income Net -
Net Interest Income $31M
Interest Income -
Interest Expense $31M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.5M
Income Before Tax -$207M
Income Tax Expense $8.2M
Interest And Debt Expense -
Net Income From Continuing Operations -$215M
Comprehensive Income Net Of Tax -
Ebit -$272M
Ebitda -$270M
Net Income -$215M

MRUS News

MRUS Profile

Merus BV Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Merus NV is a clinical-stage biotechnology company based in Utrecht, Netherlands, specializing in the discovery and development of innovative bispecific antibody therapies targeting cancer. With a strong focus on advancing its proprietary platforms, Merus leverages its unique technology to create targeted treatments that enhance immune responses against tumors. As it progresses through various stages of clinical development, Merus aims to address significant unmet medical needs in immuno-oncology, positioning itself as a key player in the evolving landscape of cancer therapeutics.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.16%
$7.98
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
JOBY
-1.59%
$14.16
BTG
+0.46%
$4.34
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
UBER
-4.95%
$92.98
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
AMZN
-1.40%
$230.76
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
CLSK
+2.14%
$11.44
JBLU
0.00%
$5.07
HIMS
-1.08%
$50.34
ETWO
0.00%
$3.30
CAN
+0.23%
$0.80
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
IONZ
-10.28%
$4.80
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.16%
$7.98
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
JOBY
-1.59%
$14.16
BTG
+0.46%
$4.34
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
UBER
-4.95%
$92.98
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
AMZN
-1.40%
$230.76
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
CLSK
+2.14%
$11.44
JBLU
0.00%
$5.07
HIMS
-1.08%
$50.34
ETWO
0.00%
$3.30
CAN
+0.23%
$0.80
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
IONZ
-10.28%
$4.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.